

PROVIDER Update



CONTRACTUAL | OCTOBER 1, 2024 | UPDATE 24-1056 | 5 PAGES

New: 3rd Quarter 2024 Injectable Medication HCPCS/DOFR Crosswalk

Use the updates for dates of service on and after December 6, 2024

The Health Net* Pharmacy Advisory Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The Pharmacy Advisory Committee members include physicians and pharmacists.

The approved updates, effective December 6, 2024, are listed on pages 2-5 of this update. Injectable medications are placed in DOFR categories that mirror the DOFR matrix categories in the Health Net* *Provider Participation Agreement (PPA)*.

The update includes:

- 22 new injectable medications to be added to the DOFR crosswalk.
- 14 updates and changes to injectable medication procedure codes.
- 1 updated category.
- 8 updates for new generic drugs.

Additional information

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library on the provider portal at provider.healthnetcalifornia.com > *Provider Library under Quick Links*, or go directly to providerlibrary.healthnetcalifornia.com.

If you have questions regarding the information contained in this update, contact the applicable Health Net Provider Services Center listed in the right-hand column.

THIS UPDATE APPLIES TO:

- Participating Physician Groups

LINES OF BUSINESS:

- IFP
 - Ambetter HMO
 - Ambetter PPO
- Employer/Group
 - HMO/POS
 - PPO
- Wellcare By Health Net
 - Medicare Advantage (HMO)
 - Medicare Advantage (PPO)
- Medi-Cal
 - Amador
 - Calaveras
 - Inyo
 - Los Angeles
 - Molina
 - Mono
 - Sacramento
 - San Joaquin
 - Stanislaus
 - Tulare
 - Tuolumne

PROVIDER SERVICES

provider_services@healthnet.com

Ambetter from Health Net IFP
Ambetter HMO – 888-926-2164

Ambetter from Health Net IFP
Ambetter PPO – 844-463-8188

Health Net Employer Group
HMO, POS & PPO 800-641-7761

Medicare (individual & employer group)
(Wellcare By Health Net) – 800-929-9224

Medi-Cal (including CS and ECM providers)
– 800-675-6110

PROVIDER PORTAL

provider.healthnetcalifornia.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

*Health Net of California, Inc., Health Net Community Solutions, Inc. and Health Net Life Insurance Company are subsidiaries of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved.

CONFIDENTIALITY NOTE FOR FAX TRANSMISSION: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by phone or by return fax and destroy this transmission, along with any attachments. If you no longer wish to receive fax notices from Provider Communications, please email us at provider.communications@healthnet.com indicating the fax number(s) covered by your request. We will comply with your request within 30 days or less.

Additions to injectable medication HCPCS/DOFR crosswalk

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

New drugs

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9999	Anktiva®	Nogapendekin alfa inbakicept-pmln solution for intravesical use	Therapeutic injection	
J3590	Avzivi®	Bevacizumab-tnfn	Therapeutic injection	Chemotherapy ¹
J3590	Beqvez™	Fidanacogene elaparvovec-dzkt injection for intravenous infusion	Therapeutic injection	
J3590	Capvaxive™	Pneumococcal 21-valent Conjugate Vaccine Injection for intramuscular use	Therapeutic injection	Immunization
J0911	Defencath®	Heparin-taurolidine lock flush solution	Therapeutic injection	
J7799	Empaveli®	Pegcetacoplan injection for subcutaneous use NDC 73606-0010-01	Self-injectable	
J7355	iDose® TR	Injection, travoprost, intracameral implant, 1 mcg	Therapeutic injection	
J3590	Imdelltra™	Tarlatamab-dlle for injection for intravenous use	Therapeutic injection	Chemotherapy ¹
J0175	Kisunla™	Donanemab-azbt IV solution 350 mg/20 ml (17.5 mg/ml)	Therapeutic injection	
J3394	Lyfgenia®	Lovotibeglogene autotemcel suspension for intravenous infusion	Therapeutic injection	
J3590	Lynmeldy™	Atidarsagene autotemcel IV suspension	Therapeutic injection	
90683	mResvia™	RSV mRNA PreF vaccine IM suspension PreF syringe 50 mcg/0.5ml	Therapeutic injection	Immunization
J0211	Nithiodote™	Injection, sodium nitrite 3 mg and sodium thiosulfate 125 mg	Therapeutic injection	
J3590	Pyzchiva®	Ustekinumab-ttwe is biosimilar ¹ to STELARA (ustekinumab)	Self-injectable	
Q0224	Pemgarda™	Pemivibart IV solution 500 mg/4 ml (125 mg/ml)	Therapeutic injection	
J9999	Rytelo™	Imetelstat sodium for IV solution	Therapeutic injection	Chemotherapy ¹

New drugs, continued

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Ryzneuta®	Injection, efbemalenograstim alfa-vuxw, 0.5 mg	Therapeutic injection	
J3590	Selarsdi™	ustekinumab-aekn is biosimilar to Stelara®	Self-injectable	
J3590	Simlandi®	Adalimumab-ryvk auto-injector kit 40 mg/0.4ml biosimilar to Humira®	Self-injectable	
J3590	Tevimbra®	Tislelizumab-jsgr injection for intravenous use	Therapeutic injection	
Q5137	Wezlana™	Injection, ustekinumab-auub, biosimilar to Stelara®, subcutaneous, 1 mg	Self-injectable	
Q5138	Wezlana™	Injection, ustekinumab-auub , biosimilar to Stelara®, intravenous, 1 mg	Therapeutic injection	

Updates/changes to injectable medication procedure codes or medications

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS	Drug name	Generic name	Comment
J7171	Adzynma®	Adamts13 recombinant-krhn	Replaces J3590
J3247	Cosentyx®	Injection, secukinumab, IV, 1 mg	Replaces J3590
J1050	Depo-Subq Provera 104®	Medroxyprogesterone acetate Injection	Replaces J3490
91320	Comirnaty® 2024-2025	COVID-19 Vaccine, mRNA, 24-25 formula	2024-2025 formula
91319	Pfizer- BioNTech COVID-19 vaccine/five -11 years of age	COVID-19 mRNA vaccine Tris-S ages five -11 Pfizer immunization suspension 2024-2025 Formula	2024-2025 formula
91318	Pfizer- BioNTech COVID-19 vaccine/six months to four Years of age	COVID-19 mRNA Vaccine Tris-S ages 6 months-4 years of age Pfizer IM Susp 2024-2025 Formula	2024-2025 formula
J3263	Loqtorzi®	Toripalimab-tpzi, 1 mg	Replaces J9999
J2267	Omvoh™	Mirikizumab-mrkz, 1 mg Injection	Replaces J3590
J9309	Polivy®	Polatuzumab vedotin-piiq for Intravenous use	Replaces J3590
J1203	Pombiliti™	Cipaglucosidase alfa-atga for IV solution	Replaces J3590

Updates/changes to injectable medication procedure codes or medications, *continued*

HCPCS	Drug name	Generic name	Comment
J1744	Sajazir™	Icatibant acetate subcutaneous solution pre-filled syringe	New generic
J2919	Solu-Medrol®	Methylprednisolone sodium succinate for injection PF 500	Replaces J2920 and J2930
J1748	Zymfentra®	Infliximab-dyyb) injection for subcutaneous use-Celltrion USA	Replaces J3590
J3393	Zynteglo™	Betibeglogene autotemcel	Replaces J3590

Category changes

The following medications have been approved to correct the secondary category listed below.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J3590	Adbry™	Tralokinumab-ldrm injection for subcutaneous use	Self-injectable	

New generic injectable medications

The following medications have been approved as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table.

HCPCS	Drug name	Generic name	Primary category	Secondary category
J2246	Micafungin	Injection, micafungin in sodium (Baxter), not therapeutically equivalent to J2248, 1 mg	Therapeutic injection	Home health/ Infusion ²
J1598	Glycopyrrol	Injection, glycopyrrolate (fresenius kabi), not therapeutically equivalent to J1596, 0.1 mg	Therapeutic injection	
J2183	Merrem	injection, meropenem (wg critical care), not therapeutically equivalent to J2185, 100 mg	Therapeutic injection	Home health/ Infusion ²
J2468	Palonosetron	Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to J2469, 25 mcg	Therapeutic injection	Chemotherapy adjunctive ¹
J2373	Immphentiv	Injection, phenylephrine hydrochloride, 20 mcg	Therapeutic injection	

New generic injectable medications, *continued*

HCPCS	Drug name	Generic name	Primary category	Secondary category
J9075	Cyclophosphamide	Injection, cyclophosphamide, 5 mg, not otherwise specified	Therapeutic injection	Chemotherapy ¹
J0872	Daptomycin for Injection (room temperature)	Injection, daptomycin, unrefrigerated, not therapeutically equivalent to J0878 or J0873, 1 mg, Xellia	Therapeutic injection	Home health/ Infusion ²
J9258	Abraxane®	Paclitaxel protein-bound particles for injectable suspension (albumin-bound). Manufacture by Teva	Therapeutic injection	Chemotherapy ¹

HCPCS codes were taken from the Centers for Medicare & Medicaid Services HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

¹If associated with a cancer diagnosis – ICD-10 codes between C00.0-C79.9, C7A.00-C7B.8, C80.0-C96.9, D00.0-D09.9.

²When administered by a nurse in a home setting.